Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06VRA
|
||||
| Former ID |
DNC008412
|
||||
| Drug Name |
4,17-dehydroxyriccardin C
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H24O2
|
||||
| Canonical SMILES |
C1CC2=CC=CC=C2C3=C(C=C(CCC4=CC(=CC=C4)OC5=CC=C1C=C5)C=C<br />3)O
|
||||
| InChI |
1S/C28H24O2/c29-28-19-22-9-8-21-4-3-6-25(18-21)30-24-15-11-20(12-16-24)10-14-23-5-1-2-7-26(23)27(28)17-13-22/h1-7,11-13,15-19,29H,8-10,14H2
|
||||
| InChIKey |
AWANYYTXBZWDHH-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Oxysterols receptor LXR-alpha | Target Info | Inhibitor | [1] | |
| Oxysterols receptor LXR-beta | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | PPAR signaling pathway | ||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Hepatitis C | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | Nuclear Receptor transcription pathway | ||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | |||||
| PPAR Alpha Pathway | |||||
| Liver X Receptor Pathway | |||||
| Adipogenesis | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Nuclear ReceptorsWP1982:SREBP signalling | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. Epub 2008 Feb 29.Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.